High content screening (HCS) also known as high content analysis (HCA), or visual screening is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. Hence high content screening is a type of phenotypic screen conducted in cells. Phenotypic changes may include increases or decreases in the production of cellular products such as proteins and/or changes in the morphology (visual appearance) of the cell. High content screening includes any method used to analyze whole cells or components of cells with simultaneous readout of several parameters. Hence the name "high content screening".
In high content screening, cells are first incubated with the substance and after a period of time, structures and molecular components of the cells are analyzed. The most common analysis involves labeling proteins with fluorescent tags, and finally changes in cell phenotype are measured using automated image analysis. Through the use of fluorescent tags with different absorption and emission maxima, it is possible to measure several different cell components in parallel. Furthermore, the imaging is able to detect changes at a subcellular level (e.g., cytoplasm vs. nucleus vs. other organelles). Therefore a large number of data points can be collected per cell. In addition to fluorescent labeling, various label free assays have been used in high content screening.
High-content screening (HCS) in cell-based systems uses living cells as tools in biological research to elucidate the workings of normal and diseased cells. HCS is also used to discover and optimizes new drug candidates. High content screening is a combination of modern cell biology, with all its molecular tools, with automated high resolution microscopy and robotic handling. Cells are first exposed to chemicals or RNAi reagents. Changes in cell morphology are then detected using image analysis. Changes in the amounts of proteins synthesized by cells are measured using a variety of techniques such as the green fluorescent proteins fused to endogenous proteins, or by fluorescent antibodies.
The technology may be used to determine whether a potential drug is disease modifying. For example, in humans G-protein coupled receptors (GPCRs) are a large family of around 880 cell surface proteins that transduce extra-cellular changes in the environment into a cell response, like triggering an increase in blood pressure because of the release of a regulatory hormone into the blood stream. Activation of these GPCRs can involve their entry into cells and when this can be visualised it can be the basis of a systematic analysis of receptor function through chemical genetics, systematic genome wide screening or physiological manipulation.
At a cellular level, parallel acquisition of data on different cell properties, for example activity of signal transduction cascades and cytoskeleton integrity is the main advantage of this method in comparison to the faster but less detailed high throughput screening. While HCS is slower, the wealth of acquired data allows a more profound understanding of drug effects.
Automated image based screening permits the identification of small compounds altering cellular phenotypes and is of interest for the discovery of new pharmaceuticals and new cell biological tools for modifying cell function. The selection of molecules based on a cellular phenotype does not require a priori knowledge of the biochemical targets that are affected by compounds. However the identification of the biological target will make subsequent preclinical optimization and clinical development of the compound hit significantly easier. Given the increase in the use of phenotypic/visual screening as a cell biological tool, methods are required that permit systematic biochemical target identification if these molecules are to be of broad use. Target identification has been defined as the rate limiting step in chemical genetics/high-content screening.
High-content screening technology is mainly based on automated digital microscopy and flow cytometry, in combination with IT-systems for the analysis and storage of the data. “High-content” or visual biology technology has two purposes, first to acquire spatially or temporally resolved information on an event and second to automatically quantify it. Spatially resolved instruments are typically automated microscopes, and temporal resolution still requires some form of fluorescence measurement in most cases.This means that a lot of HCS instruments are (fluorescence) microscopes that are connected to some form of image analysis package. These take care of all the steps in taking fluorescent images of cells and provide rapid, automated and unbiased assessment of experiments.
The instruments on the market can be divided on the basis of price, footprint and the ethereal design qualities of the box they come in - but the most incisive difference is whether the instruments are optical confocal or not. Confocal imaging summarizes as imaging/resolving a thin slice through an object and rejecting out of focus light that comes from outside this slide. This gives higher image signal to noise and higher resolution than the more commonly applied epi-fluorescence microscopy. For many biological assays, confocal imaging is not ideal (e.g. phototoxicity issues or the need for a larger focal depth etc.). What all instruments share is the ability to take, store and interpret images automatically and most integrate into large robotic cell/medium handling platforms.
Many screens are analyzed using the image analysis software that accompanies the instrument, providing a turn-key solution. Third-party software alternatives are often used for particularly challenging screens or where a laboratory or facility has multiple instruments and wishes to standardize to a single analysis platform. The most common open-source software for high-content screening is CellProfiler, produced by the Broad Institute. Another option is HCS Analyzer, originally developed at the Institut Pasteur Korea.
This technology allows a (very) large number of experiments to be performed, allowing explorative screening. Cell-based systems are mainly used in chemical genetics where large, diverse small molecule collections are systematically tested for their effect on cellular model systems. Novel drugs can be found using screens of tens of thousands of molecules, and these have promise for the future of drug development. Beyond drug discovery, chemical genetics is aimed at functionalizing the genome by identifying small molecules that acts on most of the 21,000 gene products in a cell. High-content technology will be part of this effort which could provide useful tools for learning where and when proteins act by knocking them out chemically. This would be most useful for gene where knock out mice (missing one or several genes) can not be made because the protein is required for development, growth or otherwise lethal when it is not there. Chemical knock out could address how and where these genes work. Further the technology is used in combination with RNAi to identify sets of genes involved in specific mechanisms, for example cell division. Here, libraries of RNAis, covering a whole set of predicted genes inside the target organism's genome can be used to identify relevant subsets, facilitating the annotation of genes for which no clear role has been established beforehand. The large datasets produced by automated cell biology contain spatially resolved, quantitative data which can be used for building for systems level models and simulations of how cells and organisms function. Systems biology models of cell function would permit prediction of why, where and how the cell responds to external changes, growth and disease.
High-content screening technology allows for the evaluation of multiple biochemical and morphological parameters in intact biological systems.
For cell-based approaches the utility of automated cell biology requires an examination of how automation and objective measurement can improve the experimentation and the understanding of disease. First, it removes the influence of the investigator in most, but not all, aspects of cell biology research and second it makes entirely new approaches to possible.
In review, classical 20th century cell biology used cell lines grown in culture where the experiments were measured using very similar to that described here, but there the investigator made the choice on what was measured and how. In the early 1990s, the development of CCD cameras (charge coupled device cameras) for research created the opportunity to measure features in pictures of cells- such as how much protein is in the nucleus, how much is outside. Sophisticated measurements soon followed using new fluorescent molecules, which are used to measure cell properties like second messenger concentrations or the pH of internal cell compartments. The wide use of the green fluorescent protein, a natural fluorescent protein molecule from jellyfish, then accelerated the trend toward cell imaging as a mainstream technology in cell biology. Despite these advances, the choice of which cell to image and which data to present and how to analyze it was still selected by the investigator.
By analogy, if one imagines a football field and dinner plates laid across it, instead of looking at all of them, the investigator would choose a handful near the score line and had to leave the rest. In this analogy the field is a tissue culture dish, the plates the cells growing on it. While this was a reasonable and pragmatic approach automation of the whole process and the analysis makes possible the analysis of the whole population of living cells, so the whole football field can be measured.
- Haney SA, ed. (2008). High content screening: science, techniques and applications. New York: Wiley-Interscience. ISBN 0-470-03999-X.
- Giuliano KA, Haskins JR, ed. (2010). High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery. Totowa, NJ: Humana Press. ISBN 1-61737-746-5.
- Gasparri F (June 2009). "An overview of cell phenotypes in HCS: limitations and advantages". Expert Opinion on Drug Discovery 4 (6): 643–657. doi:10.1517/17460440902992870.
- Proll G, Steinle L, Pröll F, Kumpf M, Moehrle B, Mehlmann M, Gauglitz G (August 2007). "Potential of label-free detection in high-content-screening applications". J Chromatogr A 1161 (1-2): 2–8. doi:10.1016/j.chroma.2007.06.022. PMID 17612548.
- Burdine L, Kodadek T (May 2004). "Target identification in chemical genetics: The (often) missing link". Chem. Biol. 11 (5): 593–7. doi:10.1016/j.chembiol.2004.05.001. PMID 15157870.
- Eggert US, Mitchison TJ (June 2006). "Small molecule screening by imaging". Curr Opin Chem Biol 10 (3): 232–7. doi:10.1016/j.cbpa.2006.04.010. PMID 16682248.
- Abraham VC, Taylor DL, Haskins JR (January 2004). "High content screening applied to large-scale cell biology". Trends Biotechnol. 22 (1): 15–22. doi:10.1016/j.tibtech.2003.10.012. PMID 14690618.
- Bleicher KH, Böhm HJ, Müller K, Alanine AI (May 2003). "Hit and lead generation: beyond high-throughput screening". Nat Rev Drug Discov 2 (5): 369–78. doi:10.1038/nrd1086. PMID 12750740.
- Burdine L, Kodadek T (May 2004). "Target identification in chemical genetics: the (often) missing link". Chem. Biol. 11 (5): 593–7. doi:10.1016/j.chembiol.2004.05.001. PMID 15157870.
- Carpenter AE, Sabatini DM (January 2004). "Systematic genome-wide screens of gene function". Nat. Rev. Genet. 5 (1): 11–22. doi:10.1038/nrg1248. PMID 14708012.
- Edwards BS, Oprea T, Prossnitz ER, Sklar LA (August 2004). "Flow cytometry for high-throughput, high-content screening". Curr Opin Chem Biol 8 (4): 392–8. doi:10.1016/j.cbpa.2004.06.007. PMID 15288249.
- Xu GW, Mawji IA, Macrae CJ, Koch CA, Datti A, Wrana JL, Dennis JW, Schimmer AD (March 2008). "A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization". Apoptosis 13 (3): 413–22. doi:10.1007/s10495-007-0175-4. PMID 18181020.
- Giuliano KA, Haskins JR, Taylor DL (August 2003). "Advances in high content screening for drug discovery". Assay Drug Dev Technol 1 (4): 565–77. doi:10.1089/154065803322302826. PMID 15090253.
- Milligan G (July 2003). "High-content assays for ligand regulation of G-protein-coupled receptors". Drug Discov. Today 8 (13): 579–85. doi:10.1016/S1359-6446(03)02738-7. PMID 12850333.
- RNAiAtlas RNAi Libraries and their target analysis results (ETH Zurich)
- The Advanced Cell Classifier project (ETH Zurich)
- High Content Imaging Google Group (High Content Imaging Users Group)
- Yale Center for High Throughput Cell Biology (Yale Center for High Throughput Cell Biology)
- High-Content Screening (Purdue University)
- High-Throughput Bioscience Center (HTBC, Stanford University)
- Institut Pasteur Korea
- BioHts HCS page
- Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG)
- Molecular Screening Shared Resource (MSRI,UCLA)
- Central Drug Research Institute, Lucknow, India
- Open Screening Environment
- HCS browser and HCS-based classification
- Screening Centre KIT Karlsruhe Institute of Technology
-  Burnham Institute for Medical Research / High Content Screening Core Facility
-  Cambridge Healthtech Institute
-  HCS Analyzer
- Image Mining Group @ Institut Pasteur Korea